References

  1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987; 69(2): 454-9. PubMed | Google Scholar

  2. Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Haemost. 2014; 40(1): 17-27. PubMed | Google Scholar

  3. Annucci M. Treatment of von Willebrand's disease. N EnglJ Med. 2004; 351(7): 683-94. PubMed | Google Scholar

  4. Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost. 2011; 105(4): 647-54. PubMed | Google Scholar

  5. Lenting PJ, Christophe OD, Denis CV. Von Willebrand factor biosynthesis, secretion and clearance: connecting the far ends. Blood. 2015 Mar 26; 125(13): 2019-28. PubMed | Google Scholar

  6. Laffan MA1, Lester W, O'Donnell JS, Will A, Tait RC, Goodeve A, Millar CM, Keeling DM. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014 Nov; 167(4): 453-465. PubMed | Google Scholar

  7. Rodeghiero F, Castaman G. Textbook of Hemophilia. Oxford, UK: Blackwell Publishing; von Willebrand disease: epidemiology.2005; pp. 265-71. Google Scholar

  8. Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A, MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013 Mar 21; 121(12): 2336-9. PubMed | Google Scholar

  9. Flood VH, Lederman CA, Wren JS, Christopherson PA, Friedman KD, Hoffmann RG, Montgomery RRJ. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. Thromb Haemost. 2010 Jun; 8(6): 1431-3. PubMed | Google Scholar

  10. Othman M, Emsley J. Platelet-type von Willebrand disease: toward an improved understanding of the "sticky situation". Semin Thromb Hemost. 2014 Mar; 40(2): 146-50. PubMed | Google Scholar

  11. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008 Apr 1; 111(7): 3531-9. PubMed | Google Scholar

  12. Ames PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013 Aug 1; 122(5): 636-40. PubMed | Google Scholar

  13. Ames PD, Goodeve AC. von Willebrand disease. Genet Med. 2011 May; 13(5): 365-76. PubMed | Google Scholar

  14. De Meyer SF, Deckmyn H, Vanhoorelbeke K. Von Willebrand factor to the rescue. Blood. 2009; 113(21): 5049-57. PubMed | Google Scholar

  15. Casonato A, Steffan A, Pontara E, Zucchetto A, Rossi C, De Marco L, Girolami A. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost. 1999 Feb; 81(2): 224-8. PubMed | Google Scholar

  16. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood. 1988 Nov; 72(5): 1449-55. PubMed | Google Scholar

  17. Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, Hay CR, Hill FG, Laffan M, Peake IR. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia. 2004 May; 10(3): 218-31. PubMed | Google Scholar

  18. Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Diagnosis and management of von Willebrand disease in Spain. Semin Thromb Hemost. 2011 Jul; 37(5): 503-10. PubMed | Google Scholar

  19. Batlle J1, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 2009 Mar; 20(2): 89-100. PubMed | Google Scholar

  20. Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May; 7(3): 258-66. PubMed | Google Scholar